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ANTIGEN ARUHAN IN-VIVO Toxoplasma gondii DAN APLIKASINYA 
DALAM DIAGNOSIS TOKSOPLASMOSIS PADA MANUSIA 
 
ABSTRAK 
Toxoplasma gondii bertaburan secara meluas di seluruh dunia, dengan prevalens 
yang tinggi di kawasan tropika. Jangkitan primer oleh T.gondii dalam wanita hamil 
mungkin mengakibatkan jangkitan kongenital terhadap fetus, manakala pesakit 
jangkitan kronik dengan system imun terkompromi adalah berisiko tinggi untuk 
mengalami pengaktifan kembali penyakit tersebut di sepanjang kehidupan mereka. 
Diagnosis bagi toksoplasmosis biasanya dijalankan melalui pengesanan antibodi IgM 
dan IgG yang spesifik terhadap T.gondii. Kekurangan sensitiviti dalam kebanyakan 
ujian IgM (khususnya bagi jangkitan kongenital) dan isu spesifisiti dalam ujian-ujian 
IgG dan IgM adalah masih wujud. Oleh itu, kajian perlu dilakukan untuk 
mengenalpasti antigen T. gondii yang boleh meningkatkan ketepatan diagnosis bagi 
toksoplasmosis. 
Teknologi antigen aruhan in-vivo (IVIAT) adalah kaedah yang sesuai untuk 
mengesan antigen-antigen baru dengan nilai diagnostik, memandangkan antigen 
aruhan in-vivo dianggap berkait secara langsung dengan jangkitan manusia yang 
sebenar. Dalam kajian ini, IVIAT menggunakan saringan imun perpustakaan cDNA 
faj T. gondii dan prob IgG/IgM dijalankan menggunakan serum terjerap daripada 
pesakit yang mempunyai bukti serologi bagi jangkitan kronik dan akut. Penjerapan 
serum dilakukan menggunakan tiga persediaan antigen yang berbeza daripada setiap 
sel E.coli XL-1 Blue MRF’ dan T. gondii yang ditumbuhkan secara in-vitro; 
seterusnya serum terjerap tadi digunakan untuk menyaring perpustakaan cDNA faj 
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ekspresi T.gondii. Klon yang mempamerkan reaktiviti yang tinggi kemudiannya 
dijujuki, dan klon yang mempunyai homologi yang tinggi dengan T.gondii 
seterusnya dianalisis kadar pengekspresannya menggunakan PCR masa-nyata 
kuantitatif.  
Melalui IVIAT yang menggunakan serum kronik dan prob IgG,8 klon reaktif telah 
ditemui memiliki homologi yang tinggi terhadap gen T.gondii. Analisis 
pengekspresan melalui PCR masa-nyata kuantitatif. menunjukkan ‘SAG-1 related 
sequence 3’(SRS3) dan dua gen hipotetikal adalah ‘up-regulated’ secara in-vivo 
relatif kepada tahap pengekspresannya secara in-vitro. Melalui IVIAT menggunakan 
serum akut, 29 klon reaktif dari setiap saringan imun IgM dan IgG telah ditemui 
mempunyai homologi yang tinggi dengan gen T. gondii. Analisis pengekspresan 
PCR masa-nyata kuantitatif menunjukkan bahawa 21 gen yang dikesan oleh IgM dan 
11 gen yang dikesan oleh IgG adalah ‘up-regulated’ secara in-vivo relatif kepada 
tahap pengekspresannya secara in-vitro. Empat belas klon menunjukkan lebih 
daripada 10 kali ganda tahap pengekspresan secara  in-vivo berbanding secara in-
vitro. Satu klon yang dikesan oleh IgM (AM15) telah ditemui secara ekslusifnya 
diekspreskan secara in-vivo tetapi bukan in-vitro, dengan kadar ‘fold change’ 
sebanyak 1217. Dengan menggunakan sampel serum individu, klon ini menunjukkan 
sensitiviti yang tinggi (100%, n=18) dan spesifisiti yang tinggi (100%, n=10) bagi 
mengesan antibodi T. gondii spesifik IgM. Ia dikenalpasti sebagai gen yang 
mengekspreskan RAP ‘domain-containing protein’ (TGME49_269830).  
Jujukan sisipan DNA bagi klon AM15 telah di ‘custom-cloned’ ke dalam vektor 
ekspresi (pET28), diikuti oleh pengekspresan dan penulenan protein rekombinan 
(TgRA15); dan pengesahan identity oleh MALDI-TOF-TOF. Protein rekombinan 
TgRA15 menunjukkan 100% (15/15) sensitiviti diagnostik dan 97% (29/30) 
xxiv 
 
spesifisiti diagnostik untuk mengesan antibodi IgM anti-Toxoplasma. Satu ‘lateral 
flow dipstick dot test’ menggunakan protein rekombinan TgRA15 telah dibangunkan 
dan ia menunjukkan 100% (27/27) sensitiviti diagnostik dan 97% (29/30) spesifisiti 
diagnostik untuk pengesanan IgM Toxoplasma. 
Secara kesimpulannya, kajian ini telah mengenalpasti beberapa antigen aruhan in-
vivo menggunakan sampel serum daripada pesakit akut dan kronik yang dijangkiti 
oleh Toxoplasma, dan prob IgM dan IgG. Antaranya, klon AM15 yang dikenalpasti 
menggunakan prob IgM, secara eksklusif diekspresi secara in-vivo. Protein 
rekombinan tulen TgRA15, menunjukkan sensitiviti dan spesifisiti diagnostik yang 
tinggi, dan ujian ‘dipstik dot’ yang dibangunkan menggunakannya menunjukkan 
potensi yang baik untuk diaplikasikan sebagai ujian pantas IgM bagi mengesan 
penyakit toksoplasmosis pada manusia.  
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IN-VIVO INDUCED ANTIGENS OF Toxoplasma gondii AND THEIR 
APPLICATION IN DIAGNOSIS OF HUMAN TOXOPLASMOSIS 
 
ABSTRACT 
Toxoplasma gondii is widely distributed throughout the world, with higher 
prevalence in tropical areas. Primary infection with T. gondii during pregnancy may 
result in congenital infection of the fetus while chronically-infected patients with 
compromised immune system are at higher risk for reactivation of the disease later in 
their life. Diagnosis of T. gondii infection is usually performed by detection of IgM 
and IgG antibodies against T. gondii. The lack of sensitivity in many IgM tests 
(particularly for congenital infection) and issues of specificities in IgG and IgM tests 
still exist. Thus research is still needed to identify T. gondii antigens that can 
improve the accuracy of diagnosis of toxoplasmosis. 
In-vivo induced antigen technology (IVIAT) is a promising method for identification 
of new antigens of diagnostic value, since in-vivo expressed antigens are thought to 
be directly related to the actual human infection. In this study, IVIAT using T. gondii 
cDNA phage library immunoscreening and IgG/IgM probes were performed using 
pre-absorbed sera from patients with serological evidence of chronic and acute 
infection. Sera pre-adsorption was performed against three different preparations of 
antigens from in-vitro-grown cells of each E. coli XL1-Blue MRF’ and T. gondii; 
subsequently the adsorbed sera was used to screen T. gondii cDNA phage expression 
library. The strongly reactive clones were sequenced, and those with high homology 
to T. gondii were subjected to expression analysis using quantitative real-time PCR.   
With IVIAT using chronic sera and IgG probe, 8 reactive clones were found to have 
high homology to T. gondii genes. Expression analysis using real-time PCR showed 
that SAG-1 related sequence 3 (SRS3) and two hypothetical genes were up-regulated 
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in-vivo relative to their expression levels in-vitro. With IVIAT using acute sera, 29 
reactive clones from each IgM and IgG immunoscreenings were found to have high 
homology to T. gondii genes. Real-time PCR expression analysis showed that 21 
IgM-detected genes and 11 IgG-detected genes were up-regulated in-vivo relative to 
their expression levels in-vitro. Fourteen clones showed more than 10 times fold 
expression levels in-vivo as compared to in-vitro. An IgM detected clone (AM15) 
was found to be almost exclusively expressed in-vivo but not in-vitro, with 1217 fold 
change. Using individual serum samples, this clone showed high sensitivity (100%, 
n=18) and specificity (100%, n=10) for detection of T. gondii-specific IgM antibody. 
It was identified as a gene that expresses RAP (RNA associated protein) domain-
containing protein (TGME49_269830).  
The DNA sequence insert of AM15 clone was custom-cloned into an expression 
vector (pET 28), followed by expression and purification of the recombinant protein 
(TgRA15); and confirmation by MALDI-TOF-TOF. The TgRA15 recombinant 
protein demonstrated 100% diagnostic sensitivity (n=15) and 97% specificity (29/30) 
for detection of anti-Toxoplasma IgM antibody. A lateral flow dipstick dot test using 
TgRA15 recombinant protein was developed and it showed 100% diagnostic 
sensitivity (n=27) and 97%  specificity (29/30) for Toxoplasma IgM detection.  
In summary, this study has identified a panel of in-vivo induced antigens using serum 
samples from acute and chronic Toxoplasma-infected patients, and IgM and IgG 
probes. Among them, clone AM15 identified using IgM probe, was found to be 
exclusively and highly expressed in-vivo. The purified recombinant protein TgRA15, 
showed high diagnostic sensitivity and specificity; and the dipstick dot test 
developed using this recombinant antigen showed good potential for application as 
an IgM rapid test to diagnose human toxoplasmosis.  
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 CHAPTER ONE 
INTRODUCTION 
 
1.1  Overview of Toxoplasma gondii and toxoplasmosis 
Toxoplasma gondii is an obligate intracellular parasite from the the phylum 
Apicomplexa. It is capable of producing life-long chronic infection in humans and 
warm blooded animals especially in the tropical countries. Approximately one third 
of the world’s population is infected with this protozoan parasite. Environmental, 
cultural factors and eating habits are thought to be key contributing factors in 
transmission of this infection. The word Toxoplasma comes from the Greek world 
toxon that mean “bow” and plasmid which mean “form”. Cats and other Felidae 
members are the definitive hosts for this parasite where the sexual phase occurs 
(Dubey, 2008; Thompson et al., 2009).  
 
Toxoplasmosis is divided into three groups; congenital toxoplasmosis, acquired 
toxoplasmosis and reactivated/ recrudescent toxoplasmosis. Acquired toxoplasmosis 
is caused by consumption of food or water contaminated with the parasite from 
faeces of infected cats. Congenital toxoplasmosis is the result of transmission of the 
parasite from infected mother to her unborn child. In immunocompetent individuals 
infection is usually asymptomatic and these people remain chronically infected with 
presence of cysts in the body especially brain. However during immunosuppression, 
reactivations of the disease can occur due to the conversion of slowly dividing 
bradyzoites into rapidly proliferating tachyzoites which may be influenced by genetic 
predisposition or diversity in virulence between different parasite strains (Kopecna, 
2006; Dubey, 2010; Feustel et al., 2012). 
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1.2  Historical background and taxonomy 
T. gondii was initially found in the liver and lymph of the gundi (Ctenodactylus 
gundi), a small rodent from North Africa by Charles Nicolle and Louis Manceaux in 
1908 and independently by Splendore in Brazil. Then the same parasite was found by 
Mello in the lung of a dog in Turin Italy. He was also the first to report on acute 
canine toxoplasmosis (Miro et al., 2008; Ferguson, 2009).  However the first case of 
human toxoplasmosis with the description of Toxoplasma-like organisms was 
identified in human retinal tissue by the ophthalmologist Josef Jankú from 
Czechoslovakia in 1923. The parasite was isolated from retinal tissue of neonates 
followed by additional reports on congenital infection caused by this parasite by 
Wolf in 1939. The life cycle of this parasite remained unknown until 1970, when 
several scientists found that the definitive host is the cat. Genetic diversity among T. 
gondii strains from animals and humans was first performed by Lehman in 2006 who 
reported geographic differences; including some strains which were found to be 
limited to Brazil only while others were found to be worldwide. Mapping of T. 
gondii genome was performed by Dubey in 2005 (Miro et al., 2008; Dubey 2008; 
Ferguson, 2009). According to the classical taxonomy, the parasite was placed in the 
domain Eukarya, kingdom Alveolata, phylum Apicomplexa, class Coccidia, order 
Eucoccidiorida, family Sarcocystidae, genus Toxoplasma and species T. gondii 
(Pereira et al., 2010). Figure 1.1 shows the taxonomical classification of 
Apicomplexan parasites including T. gondii. 
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Figure 1.1 Taxonomical classifications of Apicomplexan parasites including 
Toxoplasma (Roberts and Janovy, 2005). 
 
 
 
 
 
 
 
 
 
 
4 
 
1.3 Morphology  
There are three infectious stages of T. gondii; i.e tachyzoites (in groups or clones), 
bradyzoites (in tissue cysts), and sporozoites (in oocysts) (Dubey, 2008) as shown in 
Figure 1.2.   
 
1.3.1 Tachyzoites 
Frenkel in 1973 for the first time assigned the term “tachyzoite” (tachos = speed in 
Greek) to describe the rapidly multiplying stage in an intermediate host cell and in 
non-intestinal epithelial cells of definitive host. The term “tachyzoite” replaces the 
term “trophozoite” (trophicos = feeding in Greek) which was previously used. 
Tachyzoites have also been termed endozoites or endodyozoites. Aggregates of 
multiple tachyzoites are called terminal colonies, clones, or groups. The tachyzoite is 
a crescent shaped structure, approximately 2 by 6 µm (Figure 1.2a), with a pointed 
anterior (conoidal) end and a rounded posterior end. Ultrastructurally, the tachyzoite  
is composed of various organelles and inclusion bodies such as a pellicle (outer 
covering), polar rings, apical rings, micronemes, conoid, micropore, rhoptries, 
mitochondrion, golgi complex, endoplasmic reticulum, subpellicular microtubules, 
rough and smooth endoplasmic reticula, micropore, ribosomes, dense granules, 
nucleus, amylopectin granules  (which might be absent), and a multiple-membrane-
bound plastid- like organelle which has also been called a golgi adjunct or apicoplast. 
The nucleus is usually situated toward the central area of the cell and contains 
clumps of chromatin and a centrally-located nucleolus (Dubey et al., 1998; Dubey, 
2010). 
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A) Tachyzoites stained with Giemsa 
B) Cyst in the brain containing bradyzoites 
C) Unsporulated oocyt 
D) Sporulated oocyt 
 
Figure 1.2 Images of tachyzoites, bradyzoites and oocysts of T. gondii 
 (Robert-Gangneuxa and  Dardéc, 2012) 
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This proliferative form can infect every kind of nucleated cells including phagocytic 
and non-phagositic cells by active transportation (Waree, 2008). Goldman in 1958 
introduced endodyogeny as a specialized kind of multiplication which occurs when 
two progeny form inside the parent parasite. The replication of tachyzoites inside the 
host cells leads to damage and rupture of the cells. The release of tachyzoites into the 
blood stream causes intense inflammatory response and tissue infection especially 
for some organs such as eyes, skeletal and heart muscle. When the host immune 
response system takes control of infection process, the tachyzoites which are 
responsible for acute stage of infection transform to slowly dividing bradyzoites that 
are related to chronic stage of infection (Montoya and Liesenfeld, 2004; Waree, 
2008; Dubey, 2010). Figure 1.3 shows the schematic image of structures of 
tachyzoites. 
 
1.3.2 Bradyzoites 
Frenkel in 1973 coined the term “bradyzoite” (brady = slow in Greek) to describe the 
slowly multiplying organism within a tissue cyst responsible for producing life-long 
chronic infection of the host. Bradyzoites are also called cystozoites (Figure 1.2b).  A 
young cyst is small; 5 µm diameter with two bradyzoite inside it while others which 
are not so young contains thousands or hundreds of bradyzoites (Dubey, 2010). 
Tissue cysts with bradyzoites mostly form in visceral organs such as liver, lung and 
has predilection for muscular and neural tissues such as cardic and skeletal muscles, 
brain and eyes (Dubey, 2010). These cysts become important in the case of 
immunosuppressed people in whom the cyst may rupture and release the bradyzoites 
which transform back to rapidly dividing tachyzoites that lead to the reactivated 
infection (Montoya and Liesenfeld, 2004; Lindsay and Dubey, 2009).  As shown in 
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Figure 1.3, the internal structures of bradyzoite are similar to tachyzoite, however   
nucleus of the bradyzoite is located toward the posterior end; whereas in the nucleus 
of a tachyzoite is more centrally situated. In addition the content of the rhoptry in 
bradyzoite is electron dense, while those in tachyzoites are complex (labyrinthine) 
(Dubey, 2010).  
 
1.3.3 Oocysts 
Oocyst is the sexual form of T. gondii, with subspherical to spherical shape, 10 by 12 
µm in diameter. Unsporulated oocyts (Figure 1.2c) can be found in the faeces of cats 
following completion of sexual stage in the epithelium of the feline gut; and 
sporulation occurs outside the definitive host within 1 to 5 days after excretion, 
depending upon temperature and aeration (Miro et al., 2008). Sporulated oocysts 
(Figure 1.2d) have sub-spherical to ellipsoidal shapes and 11 by 13 µm diameter. 
Each oocyst contains two ellipsoidal sporocysts, each measuring 6 by 8 µm in 
diameter and contains four sporozoites. When the sporocysts are digested by 
mammals including humans, they become infected (Montoya and Liesenfeld, 2004). 
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Figure 1.3 Schematic drawings of tachyzoite (left) and bradyzoite (right) of T. 
gondii. Drawings are composites of electron micrograohs 
(Dubey et al., 1998) 
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1.4 Life cycle of T. gondii 
T. gondii is a parasite with a heteroxenous life cycle, requiring different animal hosts 
to complete its life cycle. The definitive hosts for this parasite are family of Felidae, 
either domestic cats or other felids such as ocelots, jaguarundi, margays, bobcats, 
Bengal tiger and Pallas cats. Invertebrates such as flies, earthworms and cockroaches 
can spread oocysts mechanically (Torda, 2001, Nutter et al., 2004). The sexual phase 
of T. gondii takes place in the gut intestinal epithelium of the cat, starting with 
ingestion of tissue cysts containing the bradyzoite (Figure 1.4). After that the cyst 
wall is digested by the gastric acid, lytic enzymes and bile of the upper digestive 
tract. The bradyzoites are released and invade the gut intestinal epithelium followed 
by bradyzoites conversion into invasive tachyzoites stage with systemic 
dissemination. 
 
Meanwhile some parasites inside the epithelium pass five different stages gradually 
where one tachyzoite produce two daughter cells by schizogeny, together with 
formation of multiple merozoite around a previously divided nucleus (Dubey et al., 
1998). The sexual stages (or gamete) are produced three to fifteen days after cyst 
ingestion.  Several bi-flagellated microgametes formed through mature male gamete 
division, and in parallel with development of a female gamete. The sexual stage takes 
place only in the microwilli of the small intestine of the definitive host cell 
microvilli, especially the ileum. Aided by its flagella, the male microgamete fertilizes 
the female gamete and forms a zygote within a thick walled oocyst. Oocysts are 
released from the ruptured epithelial cells into the intestinal lumen of the definitive 
host and excreted as unsporulated oocysts into the environment via the cat faeces.  
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Figure 1.4 Summary of the life cycle of T. gondii 
   (Ferguson, 2009) 
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After 1-20 days, two internal sporocysts containing four sporozoites are produced 
inside the oocysts.Since oocyts are very resistant to variations of environmental 
conditions; they can maintain their infectivity for a long time until ingested by a new 
host (Dubey, 2004; Jones and Dubey 2010). 
 
Ingestion of oocysts by intermediate (non-feline) hosts including humans will result 
in systemic infection; while ingestion of oocyts by other felines leads to formation of 
sexual stages as well as systemic infection. After primary invasion of epithelial cells 
in a new host, the sporozoites convert to the actively proliferative tachyzoite form. 
Reproduction via asexual proliferation (endodyogeny) takes places in the intestinal 
epithelium followed by crossing of the lamina propria. The tachyzoites rapidly move 
from the intestinal tract to muscles and internal organs, especially the brain, to 
establish a latent infection which occurs by conversion of tacyzoites to the slowly 
replicating bradyzoites. Enclosed in the tissue cysts, the slowly replicating 
bradyzoites are viable for many months to many years, if not for the whole life of the 
host. Persistent chronic infection in tissues helps at some time point to ensure that the 
parasite will be transferred to a new host through consumption of raw or 
undercooked meat from infected animals (Dubey, 2004; Dubey, 2008; Jones and 
Dubey 2010). Humans are susceptible to Toxoplasma infection either through tissue 
cysts in undercooked meat from other intermediate hosts such as sheep, goat, cow or 
pigs or from ingestion of oocysts containing sporozoites in environment. The 
widespread prevalence of felines ensures worldwide dissemination of this parasite 
via environmental oocyst contamination (Dubey, 2004; Behnke et al., 2014).  
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1.5 Epidemiology  
Toxoplasmosis is a widespread infectious disease in animals and men, with variable 
prevalence from country to country and also different regions of a country depending 
on socio-economic habits and climates. The seroprevalence of T. gondii infection in 
various regions throughout the world is up to 90% in some populations; it is often 
higher in areas with hot, humid climates and lower altitudes which favour survival of 
oocysts and appears to be lower in colder areas. Under suitable circumstances (i.e. in 
moist, warm soil), oocysts can survive for approximately 1 year while they do not 
survive well in cold, arid climates ( Sukthana, 2006; Pappas et al., 2009; Innes 2010). 
 
 In the United State, the prevalence of this infection appears to be declining. During 
1988–1994 a seroprevalence of 14.1% was found in 12–49 years persons, whereas a 
seroprevalence of 9.0% was found for the same age group during 1999–2004 (Nutter 
et al., 2004, Pappas et al., 2009). According to a report by Tenter et al. (2000) on T. 
gondii prevalence in women at child-bearing age (1990–2000), the rates of positive 
seroprevalence, were 51–72% in several Latin-American countries, 58% in Central 
European countries, and 54–77% in West African countries. Low seroprevalence (4–
39%) was reported in southwest Asia, Korea and China as well as in cold and arid 
climate areas such as Scandinavian countries (11–28%). The seroprevalence of this 
disease was reported to be 28.3% for women in southern Thailand (Nissapatorn et 
al., 2011). Seropositive prevalence of T. gondii in the same country may differ 
among geographical regions or populations and world-wide prevalence in older 
populations is higher (Tenter et al., 2000, Pappas et al., 2009). It has also been 
reported that the seroprevalence of T. gondii infection in USA is less compared with 
that in Latin America, central Europe and sub-Saharan Africa; however the 
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seroprevalences in Scandinavian countries and in England are lower than in USA 
(Lones et al., 2001, Pappas et al., 2009).  It has also been reported that toxoplasmosis 
is widely prevalent in animals and humans in Brazil (Dubey et al., 2012). Data for 
Toxoplasma infection in Malaysia demonstrated seroprevalence of about 30% with 
highest prevalence of this disease in Malays followed by Indian (Nissapatorn and 
Abdullah, 2004). Another study reported that chronic toxoplasmosis in Malaysia was 
estimated to vary from 10-50% (Nissapatorn et al, 2003).  
 
1.6 Transmission  
Infection caused by T. gondii commonly could be seen in many animals used for 
food such as, sheep, goats, rabbits, and pigs. The probable source of T. gondii 
infection, either oocysts or tissue cysts, is affected mostly by the eating habits and 
presence of infected domestic cats in the near environment. Toxoplasma infection is 
not passed from person-to-person, except in the case of mother-to-child (congenital) 
transmission, organ transplantation or blood transfusion. Human become infected in 
one of three main ways: foodborne by ingesting T. gondii tissue cysts in the 
undercooked meat of infected food animals; animal-to-human (zoonotic) by 
ingesting infectious oocysts in soil, water and other materials contaminated by 
infected cat faeces; or mother-to-child (congenital) through vertical transplacental 
transmission of tachyzoites from mothers to the fetus (Figure 1.5). 
 
1.6.1 Congenital transmission 
Congenital toxoplasmosis is caused by vertical transmission of T. gondii from a 
seronegative acutely infected pregnant woman to her fetus. The disease was reported 
for the first time by Wolf, Cowen and Page in a human child in 1939 (Dubey, 2008).  
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Figure 1.5 Transmission of T. gondii to humans and animals 
 (Robert-Gangneuxa and  Dardéc, 2012) 
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Different factors are associated with congenital toxoplasmosis, including climate, 
route of transmission, eating habits, cultural behavior, and hygienic standards. This 
association results in marked differences among nations and populations. For 
example, the prevalence of congenital infection in France and Belgium is 2–3 cases 
per 1000 live births, significantly higher compared with US prevalence of 1 in 
10,000 to 1 in 1000 per live births. Reports from England indicates that congenital 
toxoplasmosis occur approximately 1 in 10,000 live births (Lebech et al., 1999; 
Pappas et al., 2009). Clinical manifestations of this infection in newborns are varied 
and can be developed at different times before and after birth. Majority of newborns 
infected with T. gondii in utero are asymptomatic at birth (70–90%) or may be 
unnoticed (Lebech et al., 1999). The classic triad of intracranial calcifications, 
chorioretinitis and hydrocephalus occurred in fewer than 10% of infected newborns.  
 
Microcephaly or/and hydrocephalus may occur when intra-uterine infection results in 
meningoencepahlitis (Lebech et al., 1999; Zhou et al., 2011). There may also be a 
relationship between toxoplasmosis and function of the brain, with asymptomatic 
infected infants exhibiting lower intelligence quotients (IQs) later in their adulthood 
than do their healthy counterparts (Torrey and Yolken, 2003; Jones et al., 2014). The 
risk of fetal infection and sequelae produced during the infant’s life is multifactorial, 
depending on the immunological response of the mother during parasitemia, time of 
maternal infection, parasite load and strain virulence (Ayi et al. 2009; Jones et al., 
2014). 
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The possibility of fetal infection is approximately 1% when primary maternal 
infection happens just prior to the preconception period but ascends as pregnancy 
progresses. During the first trimester of pregnancy, not treated infection acquired by 
women results in congenital infection in 10 to 25% of infants. During the second and 
third trimesters of pregnancy the incidences of fetal infection are 30–55% and 60–
65%, respectively (Lynfield and Guerina, 1997; Ayi et al., 2009; McLeod et al, 
2009). However the consequences and sequelae are more severe when infection 
occurs in first trimester of pregnancy, such as miscarriage and abortion (Jones et al., 
2014) (Figure 1.6). Manifestations of ocular toxoplasmosis at birth are less severe, 
and recurrences are fewer in those teenagers who were treated promptly early in the 
first year of life and in utero (Delair et al., 2011).  
 
It has been reported that uninfected babies were born later than infected babies. In 
addition congenital infection was associated with increased risk of preterm delivery 
if seroconversion happens before 20 weeks of gestation. Latent chronic T. gondii 
infection may be reactivated in immunodeficient patients (such as HIV-infected 
pregnant women) and may result in congenital transmission of the parasite to the 
fetus. A critical step in congenital toxoplasmosis diagnosis and evaluation of the time 
of infection is achieved via applying laboratory techniques and monitoring the 
immune response (Petersen, 2007, McLeod et al, 2009). 
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Figure 1.6 The frequency of congenital toxoplasmosis and its relation to the severity 
of consequences on fetus and gestational age 
(www.perinatology.com/exposures/infectionlist.ht) 
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1.6.2 Foodborne transmission 
Toxoplasmosis is considered as one of the infectious diseases associated with 
foodborne hospitalizations and sometimes, deaths. Undercooked meat, especially 
goat, lamb and pork; and raw vegetables and fruits with oocysts from soil 
contaminated with cat faeces are the major ways of foodborne transmission in 
humans. In a recent assessment regarding foodborne diseases in the United States, 
toxoplasmosis was reported as the second major cause of foodborne disease–related 
deaths and fourth main cause of foodborne disease–related hospitalizations 
(approximately, 4428 hospitalizations and 327 deaths annually) (Scallan et al., 2011, 
Jones et al., 2014). Recently researches have shown that T. gondii is considered as 
one of the five most important emerging pathogens involved in foodborne disease in 
the world; while in Greek toxoplasmosis was found to be one of the contributor of 
foodborne diseases to lost years of life, lived years with disability, and disability- 
adjusted lived years per million persons (9.7, 14, and 23 years, respectively) 
(Schlundt et al., 2004; Gkogka et al., 2011). 
 
Foodborne transmission of toxoplasmosis can be prevented by reducing T. gondii in 
meat via improving meat production, sufficient cooking of meat, adequate washing 
of raw vegetables and fruits, prevention of any cross contamination in the kitchen, 
and decreasing the spread of oocysts in the environment. However, based on retail 
meat samples parasitologists cannot provide a true measurement of risk for fresh 
meat since nearly half of the pork meat and a substantial portion of chicken meat are 
injected with salt and water before cooking, which can kill T. gondii tissue cysts and 
the treated products are labeled as “enhanced” meat (Schlundt et al., 2004; Dubey et 
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al., 2005). Furthermore, in the United States most of the retail chickens are sold 
frozen; another way which can kill T. gondii cysts (Schlundt et al., 2004; Jones and 
Dubey, 2012). 
 
A live vaccine for sheep which produces protective immunity for approximately 18 
months is available to protect lambs. An oral live vaccine can also prevent felines 
from shedding oocysts. Unfortunately, commercial cat vaccine production was 
discontinued because of its high cost, short shelf life, the need for a facility to keep 
the vaccine frozen and lack of concern among cat owners (Jones et al., 2014). Thus 
far vaccination for human is not available. 
 
1.6.3 Animal-to-human (zoonotic) transmission 
Human contact with infected feral cats can be considered as one the main routes for 
transmission of toxoplasmosis. Feral cats and other members of the family Felidae 
may become infected either by ingesting infectious oocysts in the environment or via 
ingesting tissue cysts containing bradyzoites from intermediate hosts. Cats which are 
allowed to hunt may acquire the infection by feeding on corpse of birds or small 
mammals infected with T. gondii. After primary infection of feral cats with tissue 
cysts, the bradyzoites turn into tachyzoites and initiate an asexual proliferation phase 
which consists of several cycles of enteric endopolygeny. The terminal stages of 
asexual proliferation commence the phase of sexual proliferation which results in the 
foundation of oocysts (Sukthana et al., 2003; Dubey, 2008; Torrey and Yolken, 
2013).  
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Cats which are kept inside the houses may shed large numbers of oocysts and 
thereby putting their owners at a serious risk of toxoplasmosis infection. Stray cats or 
cats which are roaming on farms may shed their oocysts in the environmental soil or 
water and cause contamination which may infect livestock need for human 
consumption such as sheep. However, freshly passed oocysts by cats are 
unsporulated and, therefore, direct contact with cats usually does not lead to T. 
gondii infection. If cat faeces are removed daily from the household by the owner, 
then keeping of cats inside houses or flats does not provide risk of T. gondii infection 
generally (Tenter et al., 2000; Schlundt et al., 2004; Jones and Dubey, 2012). 
 
1.6.4 Other routes of transmission  
Congenital, foodborne and zoonotic transmission are the most common ways of T. 
gondii infection transmission. There are some other routes which Toxoplasma can be 
transmitted but they are not very common; for example blood transfusion and organ 
transplantation. Organ transplant recipients can develop toxoplasmosis due to 
transmission of the parasite with the transplanted organ from a Toxoplasma-
seropositive donor to a Toxoplasma-seronegative recipient. Heart transplantation is 
the most common type of organ transplantation procedure that is at risk, as cysts are 
commonly found in the cardiac muscle (Martina et al. 2011; Derouin and Pelloux 
2012). Reynolds et al. (1996) published a case report regarding a patient who 
received a renal transplant and died one month later after transplantation. Serologic 
studies identified that primary infection with T. gondii was the main reason for his 
death.  It has also been reported that Toxoplasma can enter the human body by 
several other ways, including respiratory system, conjunctiva, and skin. Moreover, 
accidental laboratory events due to carelessness in laboratories were found as the 
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most common way of laboratory-acquired infections, where the personnel are in 
contact with contaminated glassware, needles, or particularly infected animals. There 
was also a case report of toxoplasmosis infection in a breast-fed infant whose mother 
acquired the infection (Renolds et al., 1966; Derouin and Pelloux 2012). 
 
1.7 Pathogenesis of toxoplasmosis 
Toxoplasmosis is classified into chronic and acute phases. The acute phase (early 
stage) is mostly associated with the rapidly dividing form (tachyzoite), while the 
tissue cyst is the predominant form of T. gondii during latent chronic infection. 
During early acute infection, the proliferative tachyzoites can invade every kind of 
nucleated host cells except non-nucleated red blood cells. Invasion of parasite into 
host cell is a main step in its pathogenesis.  
 
After attachment to host cell, tachyzoite enter by active phagocytosis through the 
host cell’s plasmalemma. The sequential release of proteins from the apical secretary 
organelles of parasite (micronemes, rhoptries and dense granules) assist in 
attachment and invasion into host cell and in parasitophorous vacuole generation.  
The micronemes are responsible for recognition and adhesion to the target cell while 
the rhoptry enzymes (ROP proteins) are released through a slender duct to produce 
parasitophorous vacuole; and the enzyme discharged by dense granules result in 
maturing of the vacuole as a metabolically active compartment (Zhou  et al., 2005; 
Dubey, 2008). Formation of parasitophorous vacuole, which is resistant to 
acidification, gives the parasite a chance to be in a safe environment for proliferation 
inside the cell. Their intracellular proliferation inside host cells result in necrosis and 
rupture of the cells. The liberated parasites subsequently invade and destroy 
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neighboring cells, producing larger focal lesions. Lesions or tissue necrosis could be 
found in many organs during acute toxoplasmosis, but mainly observed in liver, 
intestine, spleen, lung, pancreas and heart (Waree, 2008). If the initial Toxopasma 
infection occurs in a host during pregnancy, the tachyzoites can move throughout the 
placenta and infect the fetus, which can result in congenital infection.  
 
Liver is usually the first organ affected, it appears grossly swollen, with white foci 
randomly distributed throughout the organ. Hepatic lesions consist of necrosis and 
sometimes infiltration of heterophils. Large collections of tachyzoites are present in 
hepatocytes, resulting in the host cells degeneration (Waree et al., 2008; Bottari et 
al., 2014). The spleen may become swollen with pale yellow diffused necrotic foci. 
General necrosis is seen and fills with groups of parasites (Waree 2008). The brain of 
an acutely infected host is congested with microscopic hemorrhages. There is 
inflammatory reaction at the telencephalone and mesencephalon and T. gondii tissue 
cysts are seen near the lesions. Numerous mononuclear cells invade into the 
meninges and some mononuclear cells are seen around the vessels. With tissue cysts, 
the most notable feature is the complete absence of inflammatory cells (Kamerkar 
and Davis, 2012; Chew et al., 2012). 
 
Around three weeks after infection, as the host mount an immune response, 
tachyzoites disappear from the visceral tissues and tissue cysts are formed in neural 
and muscular tissues (Waree, 2008). The bradyzoites in the tissue cysts multiply 
slowly and can persist for the life of the host (Dubey and Frenkel, 1972; Speer and 
Dubey, 1998).  
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1.8   Strains of T. gondii 
T. gondii has an unusual population structure with three clonal lineages (I, II and III) 
which differ in epidemiological pattern of occurrence and virulence (Montoya and 
Liesenfeld, 2004). These three clonal lineages have emerged within the past 10,000 
years (Su et al., 2003). Studies show that the type I strain is highly virulent; as a 
single parasite has a lethal dose regardless of the genotype of the host. Type II and III 
strains have a 50% lethal dose of more than 10
3
 parasites and the outcome is 
dependent on the genetic background of the host (Mordue et al., 2001). Type I and II 
have been reported in human while type I often is associated with severe ocular and 
congenital disease, suggesting that it might be more pathogenic in humans. Type III 
has a common prevalence in animals (Montoya and Liesenfeld, 2004).  
 
Studies on T. gondii isolates from Brazil showed atypical genotype that they are both 
genetically and biologically different from those in the USA and Europe 
(Velmurugan et al., 2008). A recent study on T. gondii isolates from chickens in six 
different African countries (Nigeria, Congo, Egypt, Burkina Faso, Kenya and Mali) 
revealed four genotypes. Most isolates belonged to the clonal type II and III strains 
with one Nigerian isolate having an atypical genotype (Velmurugan et al., 2008). In 
Malaysia, a study on wild boars of Peninsular Malaysia showed that the predominant 
strain of T. gondii is type I (Puvanesuaran  et al, 2013a). In another local study, type 
I and II strains of T. gondii were the main isolates from free-range farm ducks 
(Puvanesuaran  et al, 2013b). In Central and South America, types I, III, strains of T. 
gondii parasites are more prevalent (Stillwaggon et al., 2011).   
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1.9 Immune response in toxoplasmosis 
T. gondii is one of the most successful parasites in the world which can produce 
asymptomatic life-long chronic infection inside the host. The immune response to 
Toxoplasma infection is unique, complicated and compartmented. It has the ability to 
acquire a balance between the immune strategies for evasion and the immune 
response of the host, with the aim of not only  maximizing the parasite proliferation, 
but also at minimizing host immunopathology (Nissapatorn and Khairul, 2004). A 
balanced interaction between neutrophils, enterocytes, dendritic cells, and 
macrophages create the immune response to T. gondii. These interactions occur 
through a complicated group of molecular signaling pathways that bring about 
regulation and activation of cytokine responses as well as production of effecter 
molecules. 
 
The high level of genetic heterogeneity background may cause individual variations 
in immune response. In addition, Toxoplasma infection has the ability to spread in all 
the organs and tissues. Each tissue compartment possesses its own specific immune 
response, especially in the placenta and in the central nervous system. An additional 
level of complexity occurred due to the possibility of reactivation of infection which 
may vary with strain virulence (Waree, 2008). 
 
During the earliest stages of infection, T. gondii is able to trigger non-specific 
response of natural killer (NK) cells, macrophage, and some other cells such as 
fibroblasts, endothelial or epithelial cells. This activation is necessary to limit 
parasite proliferation because of its cytotoxic action and to activate a specific 
